Arch Venture Partners

ARCH Venture Partners is a Chicago-based venture capital firm founded in 1986, specializing in early-stage investments in biotechnology, semiconductors, and technology sectors. The firm focuses on partnering with entrepreneurs to catalyze discoveries that prevent, detect, and cure diseases.

In September 2024, ARCH announced the closing of Fund XIII, a $3 billion fund aimed at supporting the founding and growth of early-stage biotechnology companies. This fund continues ARCH’s commitment to investing in breakthrough science and teams to advance healthcare solutions.

ARCH’s investment strategy emphasizes backing companies with transformative technologies, often originating from academic institutions and research laboratories. The firm has a history of investing in companies such as Illumina, Alnylam Pharmaceuticals, Juno Therapeutics, and Bluebird Bio, reflecting its focus on cutting-edge areas of science like RNA interference and genetic medicine.

Through its investments, ARCH Venture Partners aims to drive innovation and support the development of technologies that have the potential to significantly impact human health and well-being.